Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Free Report) in a research note released on Wednesday. The firm issued a buy rating on the biotechnology company's stock.

A number of other equities analysts have also weighed in on the company. Wells Fargo & Company decreased their price target on Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Guggenheim cut their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Scotiabank decreased their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. Finally, HC Wainwright lowered their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $1.83.

Adaptimmune Therapeutics Price Performance

ADAP stock traded up $0.02 during trading hours on Wednesday, hitting $0.30. 370,228 shares of the stock traded hands, compared to its average volume of 1,536,928. The stock has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.53. The company has a market cap of $77.43 million, a P/E ratio of -1.37 and a beta of 2.86. Adaptimmune Therapeutics has a one year low of $0.20 and a one year high of $1.48. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million during the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. Equities analysts forecast that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Two Sigma Investments LP raised its stake in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC raised its position in Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 21,688 shares in the last quarter. Invesco Ltd. lifted its stake in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 28,526 shares during the last quarter. Rock Springs Capital Management LP grew its position in Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after acquiring an additional 58,000 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 58,787 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company's stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.